ZLZhiyang Ling

Zhiyang Ling

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhiyang Ling has a total of 293 co-authors. Here are the top co-authors by number of shared publications:

  • Bing Sun

    Key Laboratory of Multi-Cell Systems, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China

    25 shared publications
  • Liyan Ma

    Key Laboratory of Multi-Cell Systems, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China

    16 shared publications
  • Chunyan Yi

    Key Laboratory of Multi-Cell Systems, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China

    13 shared publications
  • Yaguang Zhang

    State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China

    10 shared publications
  • Wangpeng Gu

    State Key Laboratory of Cell Biology, Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China

    8 shared publications
  • Xiaoyu Sun

    State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China

    8 shared publications

Latest Publications

  • Open Access

    ILC2-intrinsic IL-33 amplifies ILC2 activation and allergic lung inflammation

    by Shufen Zhong, Liming Sun, Jinxin Qiu, Bo Peng, Siying Sun, Lin Zhu, Yuying Huang, Shuangfeng Chen, Huacheng Yan, Yutong Guo, et al.

    Interleukin-33 (IL-33) from lung epithelial cells serves as a crucial alarmin to activate the lung-resident group 2 innate lymphoid cells (ILC2s) and then to initiate type 2 inflammation. However, whether IL-33 has an intrinsic role in the ILC2-driven lung inflammation remains unclear. In this study, we characterize the proteomic features of mouse lung ILC2s during activation and observe an increased expression of intrinsic IL-33 in activated ILC2s. The expression of intrinsic IL-33 in lung ILC2s can be induced by the co-stimulation of cysteinyl leukotrienes (CysLTs) and exogenous IL-33. Deletion of ILC2-intrinsic IL-33 attenuates lung inflammation by restraining ILC2 proliferation and cytokine production. Mechanistically, ILC2-intrinsic IL-33 promotes transcriptional activation of both inflammatory and proliferative signaling cascades. Additionally, ILC2-intrinsic IL-33 localizes in the nucleus and promotes the expression of Fosl2 and Nfatc1 through promoting their chromatin accessibility, leading to increased ILC2 proliferation and type 2 cytokine production. Further, we confirm that intrinsic IL-33 can be induced by co-stimulation of CysLTs and exogenous IL-33 in human ILC2s (hILC2s), which is positively related to enhanced hILC2 responses. Collectively, our findings implicate IL-33 as a nuclear factor and intrinsic amplifier of lung-resident ILC2s, operating in a positive feedback loop downstream of exogenous IL-33 and CysLTs co-stimulation to promote allergic lung inflammation.

  • Steric hindrance of antibody binding in an Omicron spike fusion intermediate

    by Zhiheng Bao, Zhimin Liu, Zhaoyong Zhang, Xuanjia Wang, Xiaohui Jin, Jiaxiu Bai, Hanwen Ma, Yaxin Li, Chunyan Yi, Zhiyang Ling, et al.

    Understanding conformational changes of the coronavirus spike protein is critical for developing broad-spectrum therapies. The pan-coronavirus epitope spike residues 815-825 (centred on the S2' site) are buried in the prefusion spike but are transiently exposed upon ACE2 binding1,2. Here, using integrated functional and structural analyses, we demonstrate that 76E1, an antibody targeting spike residues 815-825, specifically recognizes an open early fusion intermediate conformation in which this epitope adopts a helical conformation, designated the S2'-helix. SARS-CoV-2 Omicron variants evade such antibodies via steric hindrance resulting from S2'-helix shifts and restricted S1-ACE2 distancing in the early fusion intermediate conformation, together with increased reliance on cathepsin-mediated entry that impairs 76E1 inhibition of S2' cleavage. The H655Y mutation is central to this evasion. Antibody size directly affects its access to the S2'-helix. Crucially, antibody size minimization reversed the evasion mechanisms and significantly enhanced neutralizing activity against authentic Omicron variants and other human coronaviruses, including SARS-CoV-1 and HCoV-229E. These findings establish small-molecule targeting of the S2'-helix as a strategy for pan-coronavirus therapies.


  • Acute stress alleviates type 2 lung inflammation by restricting ILC2s through corticosterone-glucocorticoid receptor signaling

    by Lin Zhu, Yuying Huang, Bo Peng, Shufeng Zhong, Xiaoyu Zhang, Fuyang Xiao, Dilare Asim, Jieken Pakezhati, Jinquan Ma, Siying Sun, et al.

    The psychological state profoundly influences immune responses. While chronic stress is generally known to exacerbate inflammation, the impact of acute stress on inflammation has received far less attention. Here, we report that acute stress suppressed group 2 innate lymphoid cell (ILC2) responses, thereby alleviating type 2 lung inflammation. Restraint stress-induced acute stress activated the hypothalamic–pituitary–adrenal (HPA) axis and subsequently increased corticosterone levels. Corticosterone protected mice against lung inflammation by limiting ILC2 proliferation and type 2 cytokine production via the glucocorticoid receptor (GR). Adrenalectomy and genetic perturbation of the GR in ILC2s abolished acute stress-mediated immunosuppressive effects. Mechanistic studies revealed that corticosterone-GR signaling impaired ILC2 responses to microenvironmental factors by dampening downstream NF-κB and JAK-STAT signaling. Collectively, these findings reveal that acute stress alleviates ILC2-mediated lung inflammation through the neuroendocrine circuit and demonstrate the inhibitory role of endogenous corticosterone in ILC2 responses.

  • Open Access

    CD74-Targeting Antibody–Drug Conjugate Enhances Immunosuppression of Glucocorticoid in Systemic Lupus Erythematosus

    by Qizhen Du, Shengtao Yao, Yuying Huang, Jia Zhang, Wangmo Sonam, Xiao Lu, Jichao Yang, Shipeng Cheng, Ran Wang, Jiefang Xu, et al.

    Glucocorticoid drugs (GCs), while effective in systemic lupus erythematosus (SLE), cause severe systemic side effects due to lack of tissue-specificity. To overcome this bottleneck, we developed a CD74-directed antibody–drug conjugate (Bud-ADC) to deliver budesonide, a potent GC drug, selectively to target CD74-expressing immune cells (e.g., B cells, dendritic cells), which play an important role in SLE pathogenesis. Bud-ADC combines a cross-species anti-CD74 antibody with budesonide via a cleavable linker, enabling immunosuppression on targeted cells. In vitro, Bud-ADC selectively inhibited CD74-high immune cell activation and cytokine production. In two SLE mouse models, Bud-ADC significantly alleviated disease hallmarks—reducing autoantibodies, splenomegaly, and kidney damage—while showing superior efficacy to free budesonide at equivalent doses. The therapeutic effects involved both direct targeting of CD74-high immune cells and indirect modulation of T cell responses despite low CD74 expression. This study establishes CD74-targeted ADC as a novel strategy to enhance GC efficacy in SLE, aiming at minimizing off-target toxicity while maintaining broad immunosuppressive activity. The translatable design supports further preclinical and clinical development for autoimmune diseases.


  • Open Access

    Bispecific targeting of 4-1BB and CCR8 boosts antitumor immunity via Ti-Treg depletion and CD8+ activation

    by Jiefang Xu, Ran Wang, Shipeng Cheng, Sonam Wangmo, Jichao Yang, Fuquan Jin, Xiao Lu, Liyan Ma, Ying Zhu, Haoting Sun, et al.


  • ECM1 protects against liver steatosis through PCBP1-mediated iron homeostasis

    by Danyan Zhang, Ayiguzhali Abulitipu, Pengcheng Pang, Lei Bai, Lian Liu, Shaliyan Tuerxunmaimaiti, Wen Chen, Shuangfeng Chen, Houkun Lv, Yadong Fu, et al.

    Background and Aims: Extracellular matrix protein 1 (ECM1) is known to inhibit transforming growth factor β signalling and HSC activation, thereby attenuating liver fibrosis. RNA-seq profiling of livers from wild-type and ECM1-deficient mice revealed different enrichments in metabolic changes in fatty acid synthesis and inflammatory pathways, suggesting a regulatory role for ECM1 in liver steatosis. Here, we studied the role of ECM1 in metabolic dysfunction–associated steatotic liver disease pathogenesis and underlying mechanisms. Approach and Results: Hepatic ECM1 expression was evaluated and found to be significantly reduced in liver samples from patients with metabolic dysfunction–associated steatohepatitis (MASH), and in 4 established MASH mouse models (HFD, MCD, HFHC, and ob/ob −/− ). Although overexpression of ECM1 effectively blocked hepatic insulin resistance, steatosis, and inflammation, ECM1 ablation exacerbated diet-induced MASH progression. Mechanistically, ECM1 interacted with the K-homology 3 (KH3) domain of poly r(C) binding protein 1 (PCBP1) to suppress iron overload, mitigating lipid peroxidation and consequently impeding MASH advancement under metabolic stress. Re-expression of ECM1 and PCBP1 ameliorated liver disease progression. Conclusions: Our study reveals that ECM1 is a critical regulator in MASH, modulating lipid peroxidation by maintaining PCBP1-mediated intracellular iron homeostasis. Targeting ECM1 to restore PCBP1-dependent iron homeostasis may offer a novel therapeutic avenue for MASH.


  • Children exhibit a robust B-cell response to Omicron BA.2 after breakthrough infection with limited influence from the original antigenic sin

    by Zhiyang Ling, Zhangqian Zheng, Lingli Xu, Chunyan Yi, Xinran Dong, Xiaoqiong Gu, Xiaoyu Sun, Bingbing Wu, Bing Sun, Wenhao Zhou


  • Serum ECM1 is a promising biomarker for staging and monitoring fibrosis in patients with chronic hepatitis B

    by Lian Liu, Danyan Zhang, Rong Fan, Shipeng Cheng, Jichao Yang, Liyan Ma, Zhiyang Ling, Yaguang Zhang, Jinlin Hou, Xiaomei Wang, et al.

    It is critical to assess the extent and progression of liver fibrosis for patients to receive suitable treatments, but its diagnostic methods remain unmet. Extracellular matrix protein 1 (ECM1) has previously been reported to be a key factor in the induction and progression of liver fibrosis. However, little is known about the use of ECM1 as a biomarker to evaluate fibrosis. In a CCl4-induced mouse model of liver fibrosis, the present study demonstrated that ECM1 decreased with gradually increasing fibrosis. Using biopsy as a reference, the serum ECM1 levels decreased with increasing fibrosis stage in 247 patients with liver fibrosis, but there were no significant changes between fibrosis stage 2 and stage 0–1. To improve the performance of ECM1, age, platelet count, and ECM1 concentration were combined to calculate an EPA (ECM1-platelet-age) score (ranging from 0 to 10). The areas under the receiver operating characteristic curve of the EPA scores for the detection of F⩾2, F⩾3, and F4 were 0.6801, 0.7377, and 0.8083, respectively, which showed a comparable or significantly greater diagnostic performance for assessing fibrosis than that of the AST/ALT ratio, APRI score, or FIB-4 score. In HBV patients following antiviral treatment, the dynamics of the EPA score depended on the status of liver fibrosis development. The accuracy of the EPA score in predicting fibrosis regression and progression was 66.00% and 71.43%, respectively, while that of the LSM, another useful method for monitoring hepatic fibrosis changes during treatment, was only 52.00% and 7.14%, respectively. Compared with healthy controls, there were lower levels of serum ECM1 in HBV patients and individuals with HCV infection, MAFLD, ALD, PBC, and DILI. These findings suggested that individuals with reduced ECM1 levels may have a risk of developing liver injury, and further examinations or medical care are needed. In conclusion, the ECM1-containing EPA score is a valuable noninvasive test for staging fibrosis and predicting the progression of liver fibrosis. Additionally, ECM1 alone is an indicator for distinguishing patients with liver injury from healthy controls.


  • Open Access

    Solar ultraviolet B radiation promotes α-MSH secretion to attenuate the function of ILC2s via the pituitary–lung axis

    by Yuying Huang, Lin Zhu, Shipeng Cheng, Ranran Dai, Chunrong Huang, Yanyan Song, Bo Peng, Xuezhen Li, Jing Wen, Yi Gong, et al.

    The immunomodulatory effects of ultraviolet B (UVB) radiation in human diseases have been described. Whether type 2 lung inflammation is directly affected by solar ultraviolet (UV) radiation is not fully understood. Here, we show a possible negative correlation between solar UVB radiation and asthmatic inflammation in humans and mice. UVB exposure to the eyes induces hypothalamus-pituitary activation and α-melanocyte-stimulating hormone (α-MSH) accumulation in the serum to suppress allergic airway inflammation by targeting group 2 innate lymphoid cells (ILC2) through the MC5R receptor in mice. The α-MSH/MC5R interaction limits ILC2 function through attenuation of JAK/STAT and NF-κB signaling. Consistently, we observe that the plasma α-MSH concentration is negatively correlated with the number and function of ILC2s in the peripheral blood mononuclear cells (PBMC) of patients with asthma. We provide insights into how solar UVB radiation-driven neuroendocrine α-MSH restricts ILC2-mediated lung inflammation and offer a possible strategy for controlling allergic diseases.


  • Vitamin B6 regulates IL-33 homeostasis to alleviate type 2 inflammation

    by Songling Zhu, Shufen Zhong, Kebin Cheng, Li-Sha Zhang, Jiu-Wu Bai, Zu Cao, Su Wang, Wen Chen, Shipeng Cheng, Liyan Ma, et al.

    Interleukin-33 (IL-33) is a crucial nuclear cytokine that induces the type 2 immune response and maintains immune homeostasis. The fine-tuned regulation of IL-33 in tissue cells is critical to control of the type 2 immune response in airway inflammation, but the mechanism is still unclear. Here, we found that healthy individuals had higher phosphate-pyridoxal (PLP, an active form of vitamin B6) concentrations in the serum than asthma patients. Lower serum PLP concentrations in asthma patients were strongly associated with worse lung function and inflammation. In a mouse model of lung inflammation, we revealed that PLP alleviated the type 2 immune response and that this inhibitory effect relied on the activity of IL-33. A mechanistic study showed that in vivo, pyridoxal (PL) needed to be converted into PLP, which inhibited the type 2 response by regulating IL-33 stability. In mice heterozygous for pyridoxal kinase (PDXK), the conversion of PL to PLP was limited, and IL-33 levels were increased in the lungs, aggravating type 2 inflammation. Furthermore, we found that the mouse double minute 2 homolog (MDM2) protein, an E3 ubiquitin-protein ligase, could ubiquitinate the N-terminus of IL-33 and sustain IL-33 stability in epithelial cells. PLP reduced MDM2-mediated IL-33 polyubiquitination and decreased the level of IL-33 through the proteasome pathway. In addition, inhalation of PLP alleviated asthma-related effects in mouse models. In summary, our data indicate that vitamin B6 regulates MDM2-mediated IL-33 stability to constrain the type 2 response, which might help develop a potential preventive and therapeutic agent for allergy-related diseases.